References to Wegovy, Ozempic, Rybelsus, Mounjaro, or Saxenda, or other GLP-1 brands, are informational only
They make clinical sense when managing documented metabolic adaptation, addressing specific complaints of profound fatigue on GLP-1s, or when gastrointestinal side effects prevent the use of standard therapies
For anyone reconstituting a peptide they plan to use over several weeks such as BPC-157, TB-500, or CJC-1295/Ipamorelin this difference alone often decides which solution makes sense
Given the complex pathogenesis of NAFLD, which involves insulin resistance, abnormal nuclear receptor signaling pathways, genetic risk factors, and changes in the gut microbiota, current treatment options remain limited
These products are not compounded or manufactured by Wells Pharmacy Network